Mary Beth Beasley
Impact in
- Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Occupational and environmental lung diseases
- Oncology top 0.2%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Lung Cancer Treatments and Mutations 35
- Lung Cancer Diagnosis and Treatment 33
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 28
- Medical Imaging and Pathology Studies 20
- Occupational and environmental lung diseases 16
- Pleural and Pulmonary Diseases 13
- Oncology 36
- Lung Cancer Research Studies 14
- Cancer Immunotherapy and Biomarkers 11
- Co-authors
- William David Travis (15 shared papers)Sanja Đačić (17 shared papers)Elisabeth M. Brambilla (3 shared papers)Keith M. Kerr (10 shared papers)Ming‐Sound Tsao (10 shared papers)Fred R. Hirsch (3 shared papers)Ignacio Ivan Wistuba (4 shared papers)Yasushi Yatabe (8 shared papers)
- Journals
- Archives of Pathology & Laboratory Medicine (35 papers)Journal of Thoracic Oncology (33 papers)Modern Pathology (6 papers)CHEST Journal (5 papers)American Journal of Respiratory and Critical Care Medicine (4 papers)
- Partner nations
- United StatesUnited KingdomCanada
In The Last Decade
Mary Beth Beasley
156 papers receiving 22.5k citations
Mary Beth Beasley's Hit Papers
Peers
Comparison fields: 5 of 153
- Pulmonary and Respiratory Medicine 10.9k
- Oncology 6.3k
- Cancer Research 3.0k
- Immunology 3.0k
- Epidemiology 2.1k
Countries citing papers authored by Mary Beth Beasley
This map shows the geographic impact of Mary Beth Beasley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Beth Beasley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Beth Beasley more than expected).
Fields of papers citing papers by Mary Beth Beasley
This network shows the impact of papers produced by Mary Beth Beasley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Beth Beasley. The network helps show where Mary Beth Beasley may publish in the future.
Co-authors
The 25 scholars most cited alongside Mary Beth Beasley, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 168 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The 2015 World Health Organization Classification of Lung Tumors Hit paper breakdown → | 2015 | 3510 |
| 2 | Tissue-Resident Macrophages Self-Maintain Locally throughout Adult Life with Minimal Contribution from Circulating Monocytes Hit paper breakdown → | 2013 | 1845 |
| 3 | PD-L1 as a biomarker of response to immune-checkpoint inhibitors Hit paper breakdown → | 2021 | 1175 |
| 4 | Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology Hit paper breakdown → | 2013 | 1092 |
| 5 | Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses Hit paper breakdown → | 2017 | 963 |
| 6 | The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015 Hit paper breakdown → | 2021 | 952 |
| 7 | Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology Hit paper breakdown → | 2018 | 728 |
| 8 | The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer Hit paper breakdown → | 2016 | 594 |
| 9 | Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma Hit paper breakdown → | 2020 | 572 |
| 10 | Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Hit paper breakdown → | 2018 | 535 |
| 11 | 2005 | 472 | |
| 12 | Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group Hit paper breakdown → | 2017 | 457 |
| 13 | American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy Hit paper breakdown → | 2011 | 426 |
| 14 | Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Hit paper breakdown → | 2013 | 406 |
| 15 | Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society Hit paper breakdown → | 2020 | 390 |
| 16 | A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee Hit paper breakdown → | 2020 | 384 |
| 17 | 2010 | 359 | |
| 18 | Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group Hit paper breakdown → | 2012 | 357 |
| 19 | Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology Hit paper breakdown → | 2013 | 356 |
| 20 | 2020 | 343 |
About Mary Beth Beasley
Mary Beth Beasley is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Epidemiology, Cancer Research and Rheumatology, having authored 168 papers that have together received 23.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (35 papers), Lung Cancer Diagnosis and Treatment (33 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (28 papers), Medical Imaging and Pathology Studies (20 papers), Occupational and environmental lung diseases (16 papers), Lung Cancer Research Studies (14 papers), Pleural and Pulmonary Diseases (13 papers) and Cancer Immunotherapy and Biomarkers (11 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (10.9k citations), Oncology (6.3k citations), Cancer Research (3.0k citations), Immunology (3.0k citations) and Epidemiology (2.1k citations). Mary Beth Beasley has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include William David Travis, Sanja Đačić, Elisabeth M. Brambilla, Keith M. Kerr, Ming‐Sound Tsao, Fred R. Hirsch, Ignacio Ivan Wistuba, Yasushi Yatabe, Andrew Gordon Nicholson and Masayuki Noguchi. Their work appears in journals such as Archives of Pathology & Laboratory Medicine, Journal of Thoracic Oncology, Modern Pathology, CHEST Journal and American Journal of Respiratory and Critical Care Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.